FDA Grants Priority Review to Ripretinib for Advanced Gastrointestinal Stromal Tumors
The FDA granted a priority review to Deciphera Pharmaceuticals ’ new drug application for ripretinib to treat patients with advanced gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - February 13, 2020 Category: Cancer & Oncology Authors: Matthew Fowler Source Type: news

Deciphera Pharmaceuticals Announces U.S. Food And Drug Administration Acceptance Of New Drug Application And Priority Review For Ripretinib In Patients With Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 12, 2020-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA)... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - February 12, 2020 Category: Drugs & Pharmacology Source Type: news

Drug Trial Snapshot: AYVAKIT
AYVAKIT is used to treat adult patients with gastrointestinal stromal tumor (GIST) whose disease: is caused by certain abnormal platelet-derived growth factor receptor alpha (PDGFRA) genes and, cannot be surgically removed or, has spread throughout the body (metastatic GIST). (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 24, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
The U.S. Food and Drug Administration approved Ayvakit (avapritinib) for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) gastrointestinal stromal tumor (GIST) - a type of tumor that occurs in the gastrointestinal tract, (Source: World Pharma News)
Source: World Pharma News - January 10, 2020 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news

Ayvakit Approved to Treat GIST With PDGFRA Exon 18 Mutation
FRIDAY, Jan. 10, 2020 -- The kinase inhibitor Ayvakit (avapritinib) has been approved to treat adults with unresectable or metastatic gastrointestinal stromal tumors (GISTs) with a platelet-derived growth factor receptor alpha (PDGFRA) exon 18... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 10, 2020 Category: General Medicine Source Type: news

FDA Approves Avapritinib for Resectable or Metastatic Gastrointestinal Stromal Tumor
The FDA approved avapritinib for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumor harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. (Source: CancerNetwork)
Source: CancerNetwork - January 10, 2020 Category: Cancer & Oncology Authors: Kristie L. Kahl Source Type: news

FDA Approves Avapritinib (Ayvakit) for GIST with Mutation FDA Approves Avapritinib (Ayvakit) for GIST with Mutation
The new product is indicated for use in gastrointestinal stromal tumors (GIST) that harbor a mutation, which renders these tumors resistant to standard therapy.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation
On January 9, 2020, FDA approved avapritinib (AYVAKITTM, Blueprint Medicines Corporation) for adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including D842V mutations. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA approves the first targeted therapy to treat a rare mutation in patients with gastrointestinal stromal tumors
FDA approved Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 9, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

FDA Approves Ayvakit (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor
CAMBRIDGE, Mass., Jan. 9, 2020 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the U.S. Food and Drug... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 9, 2020 Category: Drugs & Pharmacology Source Type: news

Deciphera Pharmaceuticals Announces Submission of New Drug Application to U.S. FDA for Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
WALTHAM, Mass.--(BUSINESS WIRE)--Dec. 16, 2019-- Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ripretinib, the... (Source: Drugs.com - New Drug Applications)
Source: Drugs.com - New Drug Applications - December 16, 2019 Category: Drugs & Pharmacology Source Type: news

NIOSH Asking for National Mesothelioma Registry Input
The National Institute for Occupational Safety and Health has begun soliciting public input on the feasibility of establishing a mesothelioma registry. NIOSH is encouraging doctors, nurses, patients, families and patient advocates to provide recommendations on data collection, enrollment, registry maintenance, confidentiality and the overall usefulness of such a tool if enacted. Comments must be received by July 8, 2019. “NIOSH has a strong interest in preventing mesothelioma and helping people with the disease,” according to its outreach effort on Regulations.gov. “Mesothelioma treatments are limited, an...
Source: Asbestos and Mesothelioma News - May 1, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

Congress Funds Feasibility Study for Mesothelioma Patient Registry
The National Institute for Occupational Safety and Health will oversee a study in 2019 to determine the feasibility of establishing the first national mesothelioma patient registry. The $100,000 feasibility study was part of the $1.2 million Congress allocated in 2019 to the Centers of Disease Control and Prevention for mesothelioma research. The bulk of the funding goes toward the National Mesothelioma Virtual Bank, which is a biospecimen registry first established in 2006. It is the only federally funded program designed exclusively for the research of mesothelioma, the rare and aggressive cancer caused by asbestos expos...
Source: Asbestos and Mesothelioma News - January 15, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news

CHLA participates in novel cancer consortium announced at the Biden Cancer Summit
(Children's Hospital Los Angeles) Former Vice President Joe Biden and Dr. Jill Biden hosted the national Biden Cancer Summit, on Sept. 21, to highlight the urgent need for creating transformative approaches to cancer prevention, research and treatment. One of the new initiatives announced was the formation of a consortium to advance research into effective treatments for patients with a type of cancer called Gastrointestinal Stromal Tumor (GIST) who do not respond to current standard treatments. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 21, 2018 Category: International Medicine & Public Health Source Type: news

Gastrointestinal Stromal Tumors
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - June 27, 2018 Category: General Medicine Source Type: news

Gastrointestinal Stromal Tumors in Children
(Source: eMedicineHealth.com)
Source: eMedicineHealth.com - November 8, 2017 Category: General Medicine Source Type: news

GIST tumors linked to NF1 mutations, genetic testing needed
(University of California - San Diego) Researchers at UC San Diego Moores Cancer Center, with colleagues from Memorial Sloan Kettering Cancer Center and Fox Chase Cancer Center, have determined that a specific region of the small bowel, called the duodenal-jejunal flexure or DJF, shows a high frequency of gastrointestinal stromal tumors (GISTs) with mutations of the NF1 gene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 18, 2017 Category: International Medicine & Public Health Source Type: news

Activity of PD-1 Inhibitor Limited in Soft-Tissue Sarcomas
Treatment with the PD-1 inhibitor pembrolizumab plus metronomic cyclophosphamide had limited activity in patients with soft-tissue sarcomas and gastrointestinal stromal tumors. (Source: CancerNetwork)
Source: CancerNetwork - July 11, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: News Sarcoma Source Type: news

KIT Mutations Linked to Imatinib Response in GIST KIT Mutations Linked to Imatinib Response in GIST
Different KIT mutations have various associations with the response of gastrointestinal stromal tumors (GISTs) to adjuvant imatinib, according to results from a Scandinavian Sarcoma Group multicenter trial.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - April 3, 2017 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Immunicum begins enrolment in Phase I/II trial of INTUVAX to treat GIST
Swedish-based biopharmaceutical company Immunicum has commenced enrolment in the Phase I/II clinical trial of INTUVAX for the treatment of patients with gastrointestinal stromal tumour (GIST). (Source: Drug Development Technology)
Source: Drug Development Technology - March 8, 2017 Category: Pharmaceuticals Source Type: news

Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors Imatinib of Long-Term Help in Some Patients With GI Stromal Tumors
A substantial minority of patients with advanced gastrointestinal stromal tumors (GIST) treated with imatinib mesylate show long-term survival, according to a trial analysis presenting new molecular data.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - February 21, 2017 Category: Radiology Tags: Hematology-Oncology News Source Type: news

Study shows strong long-term survival rates for patients with GIST
Nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years, a new report outlines. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - February 20, 2017 Category: Science Source Type: news

SWOG study shows strong long-term survival rates for patients with GIST
(SWOG) Researchers show that nearly one in four patients with incurable gastrointestinal stromal tumors (GIST) treated with Gleevec will survive 10 years. Results are published in JAMA Oncology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - February 20, 2017 Category: Global & Universal Source Type: news

Clinical Insights Into Gastrointestinal Stromal Tumours Clinical Insights Into Gastrointestinal Stromal Tumours
This study examined the treatment outcomes of GISTs, highlighting some of the diagnostic and therapeutic challenges.Frontline Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 13, 2017 Category: Consumer Health News Tags: Radiology Journal Article Source Type: news

Surgery May Be Preferable in Young Adults With GI Stromal Tumors Surgery May Be Preferable in Young Adults With GI Stromal Tumors
Young adults with gastrointestinal stromal tumors (GISTs) appear to fare best after undergoing operative treatment, according to a retrospective study.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - January 26, 2017 Category: Surgery Tags: General Surgery News Source Type: news

Small intestine GIST associated with better prognosis in younger patients
Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers report findings from the first population-based analysis of AYA patients with GIST. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - January 18, 2017 Category: Science Source Type: news

Small intestine GIST associated with better prognosis in younger patients
(University of California - San Diego) Gastrointestinal stromal tumors (GIST) are tumors that arise is the wall of the digestive tract, and most often occur in the stomach or small intestine. Though more common in later in life, GISTs can occur in adolescents and young adults (AYA) under 40 years old as well. Researchers at the University of California San Diego School of Medicine report findings from the first population-based analysis of AYA patients with GIST. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 18, 2017 Category: Global & Universal Source Type: news

Columbia, NewYork-Presbyterian and non-profit Life Raft Group form cancer partnership
(Columbia University Medical Center) Collaboration will investigate the efficacy of a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 11, 2017 Category: Global & Universal Source Type: news

New gene fusions, mutations linked to gastrointestinal stromal tumors
In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, but 10 to 15 percent of adult GIST cases and most pediatric cases lack the tell-tale mutations, making identification and treatment difficult. Researchers have identified new gene fusions and mutations associated with this subset of GIST patients. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - December 15, 2016 Category: Science Source Type: news

New gene fusions and mutations linked to gastrointestinal stromal tumors
(University of California - San Diego) In recent years, researchers have identified specific gene mutations linked to gastrointestinal stromal tumors (GIST), which primarily occur in the stomach or small intestine, but 10 to 15 percent of adult GIST cases and most pediatric cases lack the tell-tale mutations, making identification and treatment difficult. Researchers at University of California San Diego School of Medicine and Moores Cancer Center have identified new gene fusions and mutations associated with this subset of GIST patients. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 15, 2016 Category: Cancer & Oncology Source Type: news

Regorafenib from Bayer submitted to health authorities seeking approval in second-line treatment of liver cancer
Bayer has announced the submission of applications to extend the marketing authorization for its oral multi-kinase inhibitor regorafenib in the U.S., Japan and Europe, for the second line treatment of patients with unresectable hepatocellular carcinoma (HCC). Regorafenib is already approved under the brand name Stivarga® in many countries to treat metastatic colorectal cancer and metastatic gastrointestinal stromal tumors. (Source: World Pharma News)
Source: World Pharma News - November 9, 2016 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

Researchers identify new drug target for gastrointestinal stromal tumors
(University of California - San Diego) Researchers at University of California San Diego School of Medicine and Mayo Clinic provide the first evidence that the Hedgehog signaling pathway is central to the formation of gastrointestinal stromal tumors (GIST), which are frequently driven by the KIT oncogene. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 1, 2016 Category: Global & Universal Source Type: news

Wedge Resection Apt for Gastrointestinal Stromal Tumors Wedge Resection Apt for Gastrointestinal Stromal Tumors
With appropriate selection and on-table gastroscopy when needed, laparoscopic nonanatomic wedge resection can deal with most gastric gastrointestinal stromal tumors (GISTs), according to Canadian researchers.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - August 24, 2016 Category: Surgery Tags: Hematology-Oncology News Source Type: news

Digital calculator provides the estimated risk for GIST recurrence
(Netmedi) Finnish digital technology company Netmedi has developed an online calculator that significantly improves the process of evaluating the risk of GIST (Gastrointestinal Stromal Tumor) recurrence and the need for additional treatment after surgery. The calculator is based on a risk analysis model published in 2012 by HUCH Cancer Center and Aalto University and is intended to be used in cancer care and research. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 17, 2016 Category: Cancer & Oncology Source Type: news

Certain gastrointestinal tumors associated with higher mortality
Certain gastrointestinal stromal tumors are more deadly than previously reported in medical literature, researchers have found, adding that further studies are needed to develop novel risk assessments for patients with these small tumors, to determine appropriate indications for surgery and/or medical therapy. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 5, 2016 Category: Science Source Type: news

Study shows certain gastrointestinal tumors associated with higher mortality
(University of California - San Diego) Researchers at University of California, San Diego School of Medicine have determined that certain gastrointestinal stromal tumors are more deadly than previously reported in medical literature. Findings are published online in the Journal of Gastrointestinal Surgery. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 5, 2016 Category: Cancer & Oncology Source Type: news

Detecting BRAF V600E-Mutated Gastrointestinal Stromal TumorsDetecting BRAF V600E-Mutated Gastrointestinal Stromal Tumors
The authors evaluated the utility of a BRAF V600E mutant-specific monoclonal antibody in the detection of BRAF-mutated GISTs. American Journal of Clinical Pathology (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - December 24, 2015 Category: Pathology Tags: Pathology & Lab Medicine Journal Article Source Type: news

Laparoscopic Surgery for Gastrointestinal Stromal TumorsLaparoscopic Surgery for Gastrointestinal Stromal Tumors
This study compares postoperative outcomes and oncologic results of laparoscopic versus open surgery for gastric gastrointestinal stromal tumors. Annals of Surgery (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - December 16, 2015 Category: Intensive Care Tags: General Surgery Journal Article Source Type: news

GIST Recurrence Risk Underestimated 'in a Third of Patients'GIST Recurrence Risk Underestimated 'in a Third of Patients'
Many patients with resected gastrointestinal stromal tumors (GIST) are missing out on recommended adjuvant therapy. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 10, 2015 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study: With GIST Patients, Be Vigilant for Other CancersStudy: With GIST Patients, Be Vigilant for Other Cancers
In this first population-based study to look at the link between gastrointestinal stromal tumors and other cancers, researchers found patients with GIST have an increased risk for other malignancies. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 7, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Esophageal Gastrointestinal Stromal Tumor EnucleationEsophageal Gastrointestinal Stromal Tumor Enucleation
How feasibile is surgical enucleation of esophageal gastrointestinal stromal tumors? Annals of Surgery (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 27, 2015 Category: Consumer Health News Tags: General Surgery Journal Article Source Type: news

New at-risk group identified for gastrointestinal stromal tumors
(University of California - San Diego) Researchers at the University of California, San Diego School of Medicine have, for the first time, clearly defined the epidemiology of gastrointestinal stromal tumors, which occur primarily in the lining of the stomach and small intestine. One key finding: Patients of Asian descent, who have not previously been identified as an at-risk population, are 1.5 times more likely than other patient groups to be diagnosed with this type of tumor. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 7, 2014 Category: Global & Universal Source Type: news

Bayer's Stivarga endorsed for gastrointestinal stromal tumors
FRANKFURT (Reuters) - German drugmaker Bayer said its Stivarga cancer drug was recommended for approval for the treatment of gastrointestinal stromal tumors by an expert panel at the European Union's healthcare regulator. (Source: Reuters: Health)
Source: Reuters: Health - June 27, 2014 Category: Consumer Health News Tags: healthNews Source Type: news

Newspath June 2013 - Gastrointestinal Stromal Tumors
Gastrointestinal stromal tumors (GISTs) are mesenchymal tumors almost exclusively occurring along the GI tract. (Source: NewsPath - Pathology News for the Medical Community)
Source: NewsPath - Pathology News for the Medical Community - June 4, 2013 Category: Pathology Source Type: news

Tool Could Help Discover New Compounds, Combinations; Quickly Identify Most Effective Gastrointestinal Stromal Tumor Treatments
A new preclinical technology enables researchers to quickly determine if a particular treatment is effective against gastrointestinal stromal tumors (GISTs), providing a boost to animal research and possibly patient care, according to new findings presented by Fox Chase Cancer Center at the AACR Annual Meeting 2013... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 11, 2013 Category: Consumer Health News Tags: GastroIntestinal / Gastroenterology Source Type: news

Stivarga Approved By FDA For Advanced Gastrointestinal Stromal Tumors (GIST)
Stivarga (regorafenib), a cancer medication, has had its usage expanded to include patients suffering from advanced gastrointestinal stromal tumors (GIST) by the U.S. Food and Drug Administration. The drug is marketed by Bayer HealthCare Pharmaceuticals. GIST occurs when cancerous cells build up inside the gastrointestinal tract. There are between 3,000 to 6,000 new cases of GIST every year in the U.S, according to data published by the National Cancer Institute. As a multi-kinase inhibitor, Stivarga prevents cancer growth by blocking the key enzymes that make the cancer spread... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - February 26, 2013 Category: Consumer Health News Tags: Colorectal Cancer Source Type: news

Horizon scanning: US FDA approves regorafenib for advanced gastrointestinal stromal tumors
Source: US FDA Area: News The U.S. Food and Drug Administration (FDA) has approved regorafenib (Stivarga) for the treatment of patients with advanced gastrointestinal stromal tumours (GIST) that cannot be surgically removed and no longer respond to other FDA-approved treatments for this disease - imatinib and sunitinib.   The approval is based on the results of the GRID trial, previously reported on the NeLM in November 2012 - please see link below details. (Source: NeLM - News)
Source: NeLM - News - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

FDA approves cancer drug Stivarga for advanced gastrointestinal stromal tumors
The US Food and Drug Administration today announced it has expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be removed and do not respond to other forms of approved… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - February 26, 2013 Category: Pharmaceuticals Source Type: news

FDA Approves Stivarga for Advanced Gastrointestinal Stromal Tumors
February 25, 2013 -- The U.S. Food and Drug Administration today expanded the approved use of Stivarga (regorafenib) to treat patients with advanced gastrointestinal stromal tumors (GIST) that cannot be surgically removed and no longer respond to... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 26, 2013 Category: Drugs & Pharmacology Source Type: news

Bayer’s Stivarga┬« (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors (for specialized target groups only)
Stivarga shown in a pivotal Phase III trial to significantly improve progression-free survival in patients with gastrointestinal stromal tumors (GIST) whose disease had progressed after previous treatments (Source: Bayer Company News)
Source: Bayer Company News - February 25, 2013 Category: Pharmaceuticals Source Type: news